Baird biotech analyst Jack Allen recaps ASH and other recent news, and shares his outlook for top names in 2025

blonca9
Dec 18, 2024
1 min read

Jack Allen discusses data that Arcellx and Vor had at last week's ASH annual meeting, and discusses Mereo, Ultragenyx, Instil Bio, Taysha Gene Therapies, and more.

Recent Posts

See All

BioVenture VoiCes Episode 18: Playground Global's Jory Bell

At a reception on the eve of Swiss Biotech Day, Swiss Biotech Association CEO Michael Altorfer introduces us to the conference and shares his thoughts on the state of biotech and global collaboration

Biotech investor Thilo Schroeder of Nextech Invest shares his take on biotech and discusses portfolio companies Revolution Medicines, Tubulis, and Circle Pharma

Baird biotech analyst Jack Allen recaps ASH and other recent news, and shares his outlook for top names in 2025

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight